EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tafenoquine: A Breakthrough Option for Babesiosis Treatment

Dongxue Ma, Mo Zhou iD, Shinuo Cao iD, Eloiza May Galon-Bedonia iD, Zhiqiang Xu, Chenghui Li, Xu Gao, Shujiang Xue, Shengwei Ji iD

Tropical Medicine and Infectious Disease · 19.05.2026 · 11 (5) · 141

DOI: 10.3390/tropicalmed11050141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tropical Medicine and Infectious Disease, online erschienen am 19.05.2026. Verfasst von Dongxue Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Jilin Provincial Department of Science and Technology, Department of Education of Jilin Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Babesiosis is a zoonosis caused by protozoan parasites of the genus Babesia. It has a worldwide distribution and affects many kinds of mammals, principally domestic animals and humans. Because there are no safe and effective vaccines available, the treatment and control for babesiosis continues to involve the use of chemotherapeutics. For years, only a few drugs have been used for clinical treatment, namely atovaquone plus azithromycin or clindamycin plus quinine for human, and imidocarb dipropionate and diminazene aceturate for domestic animals. Although screening and developing alternative drugs are continuously pursued, only a few drugs have been prospected to have clinical applications. Of these, tafenoquine has shown wide and potent antibabesial activity, offering a new option to control babesiosis. This article aims to present the current clinical therapeutic strategies for babesiosis and their limitations, as well as the prospect of tafenoquine as a promising drug to treat babesiosis.

Schlagwörter

Stichwörter der Autor:innen

babesiacidesdrug resistancenovel drugtafenoquinetick-borne diseases

Autor:innen und Institutionen

  • Department of Veterinary Medicine, Agriculture College, Yanbian University, Yanji 133000, China.
  • Swine Infectious Diseases Division, Jiangsu Key Laboratory for High-Tech Research and Development of Veterinary Biopharmaceuticals, Engineering Technology Research Center for Modern Animal Science and Novel Veterinary P…
  • Department of Basic Veterinary Sciences, College of Veterinary Medicine and Biomedical Sciences, Cavite State University, Cavite 4122, Philippines.

ORCID-Profile: Mo Zhou, Shinuo Cao, Eloiza May Galon-Bedonia, Shengwei Ji

Förderung

  • Natural Science Foundation of Jilin Provincial Department of Science and Technology
  • Department of Education of Jilin Province

Zitieren

APA

Ma, D., Zhou, M., Cao, S., Galon-Bedonia, E. M., Xu, Z., Li, C., Gao, X., Xue, S., & Ji, S. (2026). Tafenoquine: A Breakthrough Option for Babesiosis Treatment. Tropical Medicine and Infectious Disease, 11(5), 141. https://doi.org/10.3390/tropicalmed11050141

Vancouver

Ma D, Zhou M, Cao S, Galon-Bedonia EM, Xu Z, Li C, et al. Tafenoquine: A Breakthrough Option for Babesiosis Treatment. Tropical Medicine and Infectious Disease. 2026;11(5):141. doi:10.3390/tropicalmed11050141

BibTeX
@article{Ma2026,
  author = {Ma, Dongxue and Zhou, Mo and Cao, Shinuo and Galon-Bedonia, Eloiza May and Xu, Zhiqiang and Li, Chenghui and Gao, Xu and Xue, Shujiang and Ji, Shengwei},
  title = {Tafenoquine: A Breakthrough Option for Babesiosis Treatment},
  journal = {Tropical Medicine and Infectious Disease},
  year = {2026},
  volume = {11},
  number = {5},
  pages = {141},
  doi = {10.3390/tropicalmed11050141}
}
Kostenlos starten →